TY - JOUR T1 - Computed tomography quantification of emphysema in people living with HIV and uninfected controls JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00296-2018 SP - 1800296 AU - Andreas Ronit AU - Thomas Kristensen AU - Vilde S. Hoseth AU - Dalia Abou-Kassem AU - Tobias Kühl AU - Thomas Benfield AU - Jan Gerstoft AU - Shoaib Afzal AU - Børge G. Nordestgaard AU - Jens D. Lundgren AU - Jørgen Vestbo AU - Klaus F. Kofoed AU - Susanne Dam Nielsen A2 - , Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/05/24/13993003.00296-2018.abstract N2 - People living with HIV (PLWH) may be more susceptible to the development of emphysema than uninfected individuals. We assessed prevalence and risk factors for emphysema in PLWH and uninfected controls. Spirometry and chest computed tomography scans were obtained in PLWH from the Copenhagen comorbidity in HIV infection (COCOMO) Study and in uninfected controls from the Copenhagen General Population Study (CGPS) who were aged above 40 years. Emphysema was quantified using low attenuation area below −950 Hounsfield units (%LAA-950), the 15th percentile density index (PD15) and assessed by semi-quantitative visual scales. Of 742 PLWH, 21.2% and 4.7% had emphysema according to the %LAA-950 threshold with cut-offs at 5% and 10%, respectively. Of 470 uninfected controls, these numbers were 24.3% (p=0.23) and 4.0% (p=0.68). HIV was not associated with emphysema (adjusted odds ratio 1.25 [95%CI: 0.68–2.36] for %LAA-950>10%), by PD15, or by visually assessed emphysema. We found no interaction between HIV and cumulative smoking. Breathlessness and sputum production were more common in PLWH with emphysema, and emphysema seemed to be more prevalent in PLWH with airflow limitation. HIV was therefore not independently associated with emphysema but the clinical impact of emphysema was greater in PLWH than in uninfected controls.Well-treated HIV infection is not associated with emphysemaFootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Ronit has nothing to disclose.Conflict of interest: Dr. Kristensen has nothing to disclose.Conflict of interest: Dr. Hoseth has nothing to disclose.Conflict of interest: Dr. Abou-Kassem has nothing to disclose.Conflict of interest: Dr. Kühl has nothing to disclose.Conflict of interest: Dr. Benfield reports personal fees from Bristol Myers Squibb, personal fees from Gilead, personal fees from Bristol Myers Squibb, personal fees from GSK, personal fees from Bristol Myers Squibb, personal fees from GSK, non-financial support from Bristol Myers Squibb, non-financial support from Gilead, personal fees from Abbvie, outside the submitted work; .Conflict of interest: Dr. Gerstoft reports other from Gilead, other from Abbvie, other from ViiV, other from BMS, other from MSD, other from Janssen, other from Medivir, outside the submitted work; .Conflict of interest: Dr. Afzal has nothing to disclose.Conflict of interest: Dr. Nordestgaard has nothing to disclose.Conflict of interest: Dr. Lundgren has nothing to disclose.Conflict of interest: Dr. Vestbo reports personal fees from GlaxoSmithKline, personal fees from Chiesi Pharmaceuticals, personal fees from Boehringer-Ingelheim, personal fees from Novartis, personal fees from AstraZeneca, outside the submitted work; .Conflict of interest: Dr. Kofoed reports personal fees from Gilead, outside the submitted work; .Conflict of interest: Dr. Dam Nielsen reports grants from Novo Nordisk Foundation, grants from Lundbeck Foundation, grants from Rigshospiatlet Research Council, grants from Gilead, grants from MSD, grants from BMS, grants from GSK/ViiV, grants and personal fees from Gilead, personal fees from GSK/ViiV, outside the submitted work. ER -